Radiotherapy in combination with immune checkpoint inhibitors

Dirk De Ruysscher; Kobe Reynders; Evert Van Limbergen; Maarten Lambrecht

doi:10.1097/CCO.0000000000000352

Radiotherapy in combination with immune checkpoint inhibitors

Dirk De Ruysscher^*, Kobe Reynders, Evert Van Limbergen, Maarten Lambrecht

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Purpose of review

The immunomodulatory effects of ionizing radiation have long been recognized; however, so far these have not been fully exploited in clinical practice. We review the rationale to combine radiation with immune checkpoint inhibitors, which are used in standard practice.

Recent findings

Preclinical research suggests a synergy between radiotherapy and these immune checkpoint inhibitors. Whether or not this benefit translates into a clinical benefit is currently subject of ongoing research.

Summary

It is highly rational to combine radiation with immune therapy as in preclinical models and in proof of concept trials in humans it clearly can increase the antitumor immunity when given together with other immune interventions.

Original language	English
Pages (from-to)	105-111
Number of pages	7
Journal	Current Opinion in Oncology
Volume	29
Issue number	2
DOIs	https://doi.org/10.1097/CCO.0000000000000352
Publication status	Published - Mar 2017

Keywords

cancer
checkpoint inhibitors
immune therapy
radiation
radiotherapy
CELL LUNG-CANCER
IMMUNOTHERAPY
IRRADIATION
DOCETAXEL
PEMBROLIZUMAB
MULTICENTER
IPILIMUMAB
NIVOLUMAB
RADIATION
MICE

Access to Document

10.1097/CCO.0000000000000352

Cite this

@article{c6f4e193bc5f46a4b7641a976fe524f7,

title = "Radiotherapy in combination with immune checkpoint inhibitors",

abstract = "Purpose of reviewThe immunomodulatory effects of ionizing radiation have long been recognized; however, so far these have not been fully exploited in clinical practice. We review the rationale to combine radiation with immune checkpoint inhibitors, which are used in standard practice.Recent findingsPreclinical research suggests a synergy between radiotherapy and these immune checkpoint inhibitors. Whether or not this benefit translates into a clinical benefit is currently subject of ongoing research.SummaryIt is highly rational to combine radiation with immune therapy as in preclinical models and in proof of concept trials in humans it clearly can increase the antitumor immunity when given together with other immune interventions.",

keywords = "cancer, checkpoint inhibitors, immune therapy, radiation, radiotherapy, CELL LUNG-CANCER, IMMUNOTHERAPY, IRRADIATION, DOCETAXEL, PEMBROLIZUMAB, MULTICENTER, IPILIMUMAB, NIVOLUMAB, RADIATION, MICE",

author = "{De Ruysscher}, Dirk and Kobe Reynders and {Van Limbergen}, Evert and Maarten Lambrecht",

year = "2017",

month = mar,

doi = "10.1097/CCO.0000000000000352",

language = "English",

volume = "29",

pages = "105--111",

journal = "Current Opinion in Oncology",

issn = "1040-8746",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "2",

}

TY - JOUR

T1 - Radiotherapy in combination with immune checkpoint inhibitors

AU - De Ruysscher, Dirk

AU - Reynders, Kobe

AU - Van Limbergen, Evert

AU - Lambrecht, Maarten

PY - 2017/3

Y1 - 2017/3

N2 - Purpose of reviewThe immunomodulatory effects of ionizing radiation have long been recognized; however, so far these have not been fully exploited in clinical practice. We review the rationale to combine radiation with immune checkpoint inhibitors, which are used in standard practice.Recent findingsPreclinical research suggests a synergy between radiotherapy and these immune checkpoint inhibitors. Whether or not this benefit translates into a clinical benefit is currently subject of ongoing research.SummaryIt is highly rational to combine radiation with immune therapy as in preclinical models and in proof of concept trials in humans it clearly can increase the antitumor immunity when given together with other immune interventions.

AB - Purpose of reviewThe immunomodulatory effects of ionizing radiation have long been recognized; however, so far these have not been fully exploited in clinical practice. We review the rationale to combine radiation with immune checkpoint inhibitors, which are used in standard practice.Recent findingsPreclinical research suggests a synergy between radiotherapy and these immune checkpoint inhibitors. Whether or not this benefit translates into a clinical benefit is currently subject of ongoing research.SummaryIt is highly rational to combine radiation with immune therapy as in preclinical models and in proof of concept trials in humans it clearly can increase the antitumor immunity when given together with other immune interventions.

KW - cancer

KW - checkpoint inhibitors

KW - immune therapy

KW - radiation

KW - radiotherapy

KW - CELL LUNG-CANCER

KW - IMMUNOTHERAPY

KW - IRRADIATION

KW - DOCETAXEL

KW - PEMBROLIZUMAB

KW - MULTICENTER

KW - IPILIMUMAB

KW - NIVOLUMAB

KW - RADIATION

KW - MICE

U2 - 10.1097/CCO.0000000000000352

DO - 10.1097/CCO.0000000000000352

M3 - (Systematic) Review article

C2 - 28085679

SN - 1040-8746

VL - 29

SP - 105

EP - 111

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

IS - 2

ER -

Radiotherapy in combination with immune checkpoint inhibitors

Abstract

Keywords

Access to Document

Fingerprint

Cite this